Selected Scientific Papers

  • Andrikoula M, Baker D, Nesic J, Liao LM, Duka T, Prelevic GM
    The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women
    Climacteric, 2011; 14: 544-550.
  • Liao L-M, Nesic J, Chadwick P, Brooke-Wavell K & Prelevic GM
    Exercise and body image distress in overweight and obese women with Polycystic Ovary Syndrome
    Gynaecological Endocrinology, 2008; 24: 555-561.
  • Kocjan T, Tan T, Conway G, Prelevic GM
    Vitamin D status in patients with ostepenia or osteoporosis – an audit of an endocrine clinic
    International Journal for Vitamin and Nutrition Research, 2006; 76: 307-313.
  • Lewandowski KC, Komorowski J, Prelevic GM, Randeva HS
    Effects of hormone replacement therapy, type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women
    Journal of Endocrinology and Metabolism, 2006; 91:3123-3130.
  • Lewandowski KC, Komorowski J, Prelevic GM, Randeva HS
    Increased circulating levels of matrix metalloproteinase-2 and -9 in women with Polycystic Ovary Syndrome
    Journal of Endocrinology and Metabolism 2006; 91: 1173-1177.
  • Agrawal R, Sharma S, Bekir J, Conway G, Bailey J, Balen AH, Prelevic GM
    Prevalence of Polycystic ovaries and Polycystic Ovary Syndrome in lesbian women compared with heterosexual women
    Fertility and Sterility, 2004; 82: 1352-1357.
  • Randeva HS, Lewandowski KC, Drzewoski J, Prelevic GM
    Exercise decreases plasma total homocysteine in overweight young women with Polycystic Ovary Syndrome
    Journal of Endocrinology & Metabolism, 2002; 87: 4496-4501.
  • Prelevic GM, P Kwong, DJ Byrne et al.
    A cross-sectional study of the cardiovascular disease risk profile in heaqlthy postmenopausal women – differential effects of menopausal hormone replacement therapy
    Fertility & Sterility, 2002; 77: 945-951.
  • Brooke-Wavell K, Prelevic GM, Bartram C, Ginsburg J
    Influence of physical activity on response of bone mineral density to 5 year tibolone
    Maturitas, 2000; 35: 229-235.
  • Agrawal R, Prelevic GM, Conway GS et al.
    Serum vascular endothelial growth factor (VEGF) concentrations in postmenopausal women: The effect of hormone replacement therapy
    Fertility & Sterility, 2000; 73: 56-60.
  • Prelevic GM, Beljic T, Balint-Peric Lj, Ginsburg J
    Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus
    Maturitas, 1998; 28: 271-276.
  • Prelevic GM, Beljic T, Balint-Peric Lj, Ginsburg J
    Cardiac flow velocity in women with Polycystic Ovary Syndrome
    Clinical Endocrinology, 1995; 43: 677-681.
  • Prelevic GM, Ginsburg J, Maletic D, et al.
    The effects of the somatostatin analogue octreotide on ovulatory performance in women with Polycystic Ovary Syndrome
    Human Reproduction, 1995; 10: 28-32.
  • Prelevic GM & Beljic T
    The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women
    Maturitas, 1994; 20: 37-44.
  • Prelevic GM, Wurzburger MI, Balint-Peric Lj, Ginsburg J
    Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in womens with Polycystic Ovary Syndrome
    Hormone Research, 1992; 37: 125-131.
  • Prelevic GM, Wurzburger MI, Balint-Peric Lj, Nesic JS
    Inhibitory effect of Sandostatin on secretion of Luteinizing hormone and ovarian steroids in Polycystic Ovary Syndrome
    The Lancet, 1990; 336: 900-903.